Search results | Allergan

Reports

Partnering Agreements with Allergan

This report provides all the information you require to better understand Allergan and its partnering interests and activities over the past seven years.

Insights

Actavis chasing Allergan also…which way will Allergan go?

Actavis Plc plans to approach Allergan Inc again about a potential merger, as the Botox maker warms up to the possibility of a sale, people familiar with the matter said on Tuesday.

Allergan

Allergan is a top pharmaceutical company based in Irvine, California,USA

Will Allergan join Valeant’s list of acquisitions?

Allergan is currently the subject of much speculation as Valeant Pharmaceuticals looks to acquire it. Valeant Pharmaceuticals, well known for building its company via acquisitions, put in a $46 billion bid one week ago to acquire Californian based botox maker Allergan.

Allergan looks to Sanofi or J&J for acquisition

Allergan has contacted companies including Sanofi and Johnson & Johnson to see if either would be interested in acquiring the Botox maker, said people with knowledge of the matter, as it explores its options after receiving an unsolicited $45.7 billion bid from Valeant Pharmaceuticals International Inc.

Partnering with Allergan: Looking for partnerships and a higher bidder

Allergan is a multi-specialty health care company focused on discovering, developing and commercializing innovative pharmaceuticals, biologics, medical devices and over-the-counter consumer products worldwide.

Allergan: Partnering activity 2005-2013

Allergan announced over 70 partnering / licensing deals since 2005

Allergan: M&A activity 2005-2013

Allergan has also announced 11 M&A deals since 2005, with the lead deals being the merger of Inamed Corp in 2005 and MAP Pharmaceuticals in 2013

Will Allergan and Forest bid for Elan?

Sources suggest that Allergan and Forest will table rival bids to acquire Elan this week

Allergan stock slide makes company an acquisition target

Allergan’s market value has tumbled to $25 billion as investors became concerned that generic competition to its Restasis eye drops and delayed drug studies would crimp future sales growth

Allergan looks to sell lap-band and obesity unit

Allergan, one of the top 50 big pharma companies, is committed to selling the company’s obesity-treatment unit in the first half of 2013 after completing a review of the business.

Events

Sorry, your search returned no results.


Deals

Pfizer creates breaking news with Allergan purchase

US drugs giant Pfizer has sealed a deal to buy Botox-maker Allergan for $160bn (£106bn) in what is the biggest pharmaceuticals deal in history.

Actavis agrees to acquire Allergan in $66 billion deal

Actavis and Allergan have entered into a definitive agreement under which Actavis will acquire Allergan for a combination of $129.22 in cash and 0.3683 Actavis shares for each share of Allergan common stock

Valeant extends the acquisition of Allergan

Valeant Pharmaceuticals has extended the acquisition period for Allergan.

Taris Biomedical and Allergan join hands for pharma deal

Allergan has closed a transaction to acquire worldwide rights to TARIS Biomedical’s lead program in a pharma deal.

Valeant plans for a hostile takeover of Allergan

Valeant Pharmaceuticals and Pershing Square plan to approach the shareholders of Allergan for a hostile takeover.

Allergan rejects Valeant’s acquisition offer

Allergan announced that its Board of Directors has unanimously rejected the unsolicited proposal announced by Valeant Pharmaceuticals International, Inc.  on April 22, 2014.

Big pharma, Valeant bids for a merger with Allergan

Big Pharma, Valeant Pharmaceuticals International Team Up To Make $45.6 Billion Allergan Bid.

Allergan, the big pharma, sells its obesity intervention division for $110 million

Apollo Endosurgery has entered into a definitive agreement to purchase the obesity intervention division of the big pharma, Allergan for up to $110 million.

InnoCore in pharma licensing pact with Allergan

InnoCore Pharmaceuticals has signed an exclusive pharma Licensing and Collaboration Agreement with Allergan, a big pharma company.

Allergan and Medytox close pharma licensing deal for $362 million

Allergan, a big pharma company, and Medytox have entered into a pharma licensing agreement pursuant to which, upon closing, Allergan will pay Medytox an upfront payment of U.S. $65 million and Medytox will grant Allergan exclusive rights, worldwide outside of Korea, to develop and

cpbannerad300x150new2gif
rauconbadgejpg
e78banner300x150animgif
cpbannerad300x150new1gif
rauconbadgejpg
e78banner300x150animgif